XVIIIth International Symposium on Atherosclerosis 2018
ISA 2018 report: PCSK9 much yet to learn
PCSK9: Mechanistic insights can offer new therapeutic approaches With the completion of the second of the cardiovascular outcomes studies with the PCSK9 monoclonal antibodies, the PCSK9 story could be thought to be done and dusted. However, as highlighted by Dr Nabil Seidah, Director, Laboratory of…
read more »Posted on 18 June 2018 |
Posted in XVIIIth International Symposium on Atherosclerosis 2018
ISA 2018 report: ODYSSEY Outcomes analysis shows that lipoprotein(a) is a marker of cardiovascular risk
ISA 2018 provided more news from the ODYSSEY Outcomes study. According to an analysis presented by Dr Vera Bittner (University of Alabama at Birmingham, USA), baseline lipoprotein(a) was an independent predictor of major adverse cardiovascular events (MACE) in patients with a recent acute coronary syndrome…
read more »Posted on 14 June 2018 |
Posted in XVIIIth International Symposium on Atherosclerosis 2018
